Welcome to our dedicated page for CRYO CELL INTERNATIONAL SEC filings (Ticker: CCEL), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Cryo-Cell International filings document material events, governance matters, financing arrangements and exchange-listing compliance for a cord blood banking and cryogenic storage company. Recent 8-K reports cover NYSE American continued-listing standards, dividend determinations, annual meeting timing, and Regulation FD disclosures tied to company announcements.
The filing record also includes definitive proxy materials for director elections, auditor ratification, executive compensation voting and stockholder meeting procedures. Financing disclosures describe amendments to the company’s Susser Bank credit agreement, including revolving credit and term loan arrangements, subsidiary guarantor provisions involving Celle Corp., maturity terms, interest-rate mechanics and related security documents.
PORTNOY DAVID reported open-market purchase transactions in a Form 4 filing for CCEL. The filing lists transactions totaling 5,826 shares at a weighted average price of $4.17 per share. Following the reported transactions, holdings were 122,838 shares.